Inflammation and cancer prevention

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Puntoni, M ^a,b   Marra, D ^a   Zanardi, S ^a   Decensi, A ^a,c  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB;

BREAST CANCER; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG FATALITY; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; STROKE; NEOPLASM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 53449101398     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn442     Document Type: Conference Paper

References (47)

1. Kelloff GJ, Lippman SM, Dannenbeng AJ et al. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006; 12: 3661-3697.
2. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: Progress and promise, J Natl Cancer Inst 1998; 90: 1514-1528.
3. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
4. Thompson IM, Goodman PJ, Tangen CM at al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
5. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613.
6. Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, inflammation, and cancer. Ann NY Acad Sci 2004; 1028: 1-13.
7. Dannenberg AJ, Lippman SM, Mann JR et al. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266.
8. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004; 6: 203-208.
9. Crowell JA, Steele VE, Sigman CC, Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003; 2: 815-823.
10. Shureiqi I, Chen D, Lee JJ et al. 15-LOX-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000; 92: 1136-1142.
11. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42: 25-54.
12. Bettuzzi S, Brausi M, Rizzi F et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240.
13. Kwak MK, Wakabayashi N, Kensler TW. Chernoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 2004; 555: 133-148.
14. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
15. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671-674.
16. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-12.
17. Dannenberg AJ, Lippman SM, Mann JR et al. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266.
18. Chang SH, Ai Y, Breyer RM et al. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 2005; 65: 4496-4499.
19. Mao JT, Cui X, Reckamp K et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005; 7: 30-39.
20. Dasgupta K, Di Cesar D, Ghosn J et al, Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130-135.
21. Menezes RJ, Swede H, Niles R, Moysich KB, Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 251-256.
22. Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-980.
23. Platz EA, Rohrmann S, Pearson JD et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14: 390-396.
24. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
25. Sturmer T, Glynn RJ, Lee IM at al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713-720.
26. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890.
27. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
28. Benamouzig R, Deyra J, Martin A et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003; 125: 328-336.
29. Baron JA, Sandler RS, Bresalier RS et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682.
30. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884.
31. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-895.
32. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142.
33. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
34. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventon. N Engl J Mad 2005; 352: 1071-1080.
35. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004; 10: 324-330.
36. Rennert G, Almog R, Bonner JD et al. Allopurinol use and colorectal cancer risk. AACR Third Annual International Conference on Frontiers in Cancer Prevention Research, 2004, Seattle, USA, Abstr C88.
37. Gill A Maskarinec G, Wilkens LR et al. Nonsteroidal antiinflammatory drugs and breast cancer risk: The multiethnic cohort. Am J Epidemiol 2007; 166: 1150-1158.
38. Bardia A, Ebbert JO, Vierkant RA et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007; 99: 881-889.
39. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007; 18: 613-620.
40. Shen J, Gammon MD, Terry MB et al. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 2006; 8: R71.
41. Marshall SF, Bernstein L, Anton-Culver H et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Nat Cancer Inst 2005; 97: 805-812.
42. Wattenberg LW, Wiedmann TS, Estensen RD et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21: 179-182.
43. Lam S, leRiche JC, McWilliams A et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004; 10: 6502-6511.
44. Feskanich D, Bain C, Chan AT et al. Aspirin and lung cancer risk in a cohort study of women: Dosage, duration and latency. Br J Cancer 2007; 97: 1295-1299.
45. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: Results of a case control study. Int J Biol Sci 2007; 3: 328-334.
46. Hernandez-Diaz S, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007; 120: 1565-1572.
47. Muscat JE, Chen SQ, Richie JP Jr et al. Risk of lung carcinoma among users of nonsteroidal antinflammatory drugs. Cancer 2003; 97: 1732-1736.